Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DoRIS: Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls
NCT02834637Phase 3Active, not recruiting
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Feb 2017
- Primary completion
- Jan 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by London School of Hygiene & Tropical Medicine. Started Feb 2017; status: active, not recruiting.
02
Drugs
Human papillomavirus 16/18 L1 virus-like particle/AS04 vaccinerecombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT02834637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02834637.